Kennedy Keith sold $166K of CDNA

Kennedy Keith (CFO & COO) sold 2,097 shares of CareDx, Inc. (CDNA) at an average of $79.29 ($78.78–$79.61, $0.17M total) across 2 trades on 2026-11-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kennedy Keith
Published Nov 16, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

Insider selling can influence sentiment, but 10b5-1 plans are designed to reduce timing-based signaling; absent other news, the effect is usually limited.

02

Market read

A disclosed insider sale under a 10b5-1 plan, likely to have only modest near-term sentiment impact for CDNA.

03

What to watch

Traders may overreact to insider-sale headlines; the key nuance is the 10b5-1 plan and the relatively small transaction size versus typical market-moving thresholds.

Relevance 3/10Novelty 3/10Timing: filed 2026-11-16, transaction dated 2026-11-12

Background

The article is a SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CFO and COO Kennedy Keith sold $166,276 of CDNA shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, with any short-term pressure tied to optics of insider selling rather than new fundamentals.

Evidence & confidence

The filing is a Form 4 insider sale with a stated 10b5-1 plan, which typically reduces signaling value; the dollar amount is also modest for trading impact.

Market effects

Minimal, as this is company-specific insider activity with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so price impact could be negligible.

Key entities

  • CareDx, Inc.

    Company whose shares were sold by an insider under a 10b5-1 plan.

  • Kennedy Keith

    CFO and COO who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.